Stay updated with breaking news from Relational Commerce. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Revance Therapeutics, Inc. today announced that the company will host an Investor Day on September 19, 2023, from 9:30 AM ET to 1:00 PM ET. Interested parties can attend the live webcast for the...
- Provides Revance entry into the $2.5 billion U.S. therapeutic neuromodulator market.1 - Approval expands the DAXXIFY® label to include efficacy data over the 52-week ASPEN repeat dose clinical... -Today at 08:04 am- MarketScreener
- Q2 total revenue of $58.1 million, a YoY increase of 104.9%.- Q2 RHA® Collection revenue of $31.8 million, a YoY increase of 24.7%.- Q2 DAXXIFY® revenue of $22.6 million, a QoQ increase of 47.1%.- Bolstered financial position with $100 million net proceeds from ATM program and $50 million in notes available to be...
- Q2 total revenue of $58.1 million, a YoY increase of 104.9%. - Q2 RHA® Collection revenue of $31.8 million, a YoY increase of 24.7%. - Q2 DAXXIFY® revenue of $22.6 million, a QoQ increase of...
Revance Therapeutics, Inc. today announced that the company will be participating in the following investor conferences. William Blair 43rd Annual Growth Stock Conference Chief Executive Officer... | May 23, 2023